04.04.25 -- STREAM Edition: How Royalty Financing Supports Biotech Innovation

Gain insights pertinent to efficient and effective drug development. Understand and execute a risked-based critical thinking approach related to injectable drug packaging and delivery.

Explore how genetic and environmental risk factors interact to heighten Alzheimer's disease risk, and gain insight into a novel therapeutic approach.

Watch to learn about centrifuges that are designed to retain particles within a concentrated fluidized bed underneath a continuous media or buffer flow for high recovery, quality, and productivity.

Discover insights tailored specifically for drug product researchers and manufacturers, offering key knowledge on extractables, leachables, and effective implementation strategies.

Corning offers standard and custom cell culture media, vessels, and surfaces to support all growth stages. A vertically integrated supply chain ensures reliability and quality.

Electroporation enables genetic research by introducing material into cells, advancing disease modeling, gene therapy, and ion channel studies. MaxCyte technology offers scalable, efficient solutions for high-throughput applications.

Experts share strategies to accelerate ADC development, including optimizing supply chains, seamless scale-up to GMP manufacturing, and leveraging process analytical technology.

Learn about the market growth of complex molecules, driven by personalized medicine and biotechnology as well as key drivers, purification challenges, and innovative strategies for high-quality products.

XOMA Royalty’s CEO Owen Hughes and CIO Brad Sitko explain how royalty investing mitigates risks while expediting biotech drug development.

Whether you are looking to optimize your existing formulations or require full-scale manufacturing solutions, Boehringer Ingelheim BioXcellence™ is dedicated to helping you deliver impactful therapies.